{"id":"folic-acid-or-folate","safety":{"commonSideEffects":[{"rate":null,"effect":"Allergic reactions (rare)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal distension"},{"rate":null,"effect":"Anorexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Folic acid (vitamin B9) is converted to its active form, tetrahydrofolate (THF), which serves as a carrier of one-carbon units in biosynthetic reactions. These reactions are critical for the synthesis of purines and thymidylate, which are necessary for DNA replication and cell proliferation. Folic acid is essential for normal cell division and is particularly important during periods of rapid cell growth.","oneSentence":"Folic acid acts as a coenzyme in one-carbon transfer reactions essential for DNA synthesis and cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:58.007Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Folic acid deficiency anemia"},{"name":"Neural tube defect prevention in pregnancy"},{"name":"Megaloblastic anemia"},{"name":"Nutritional supplementation in various disease states"}]},"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT02676349","phase":"PHASE2","title":"Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2016-10-13","conditions":"Pancreatic Carcinoma","enrollment":130},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT06998940","phase":"PHASE3","title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-04-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":94},{"nctId":"NCT02997228","phase":"PHASE3","title":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-19","conditions":"Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":120},{"nctId":"NCT05564403","phase":"PHASE2","title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-09","conditions":"Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma","enrollment":66},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT06696768","phase":"PHASE1","title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-23","conditions":"Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8","enrollment":24},{"nctId":"NCT06628310","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-12-13","conditions":"Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":180},{"nctId":"NCT00217737","phase":"PHASE3","title":"Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09-06","conditions":"Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7","enrollment":2431},{"nctId":"NCT05355701","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-07-05","conditions":"Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer","enrollment":267},{"nctId":"NCT06365853","phase":"PHASE2","title":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-29","conditions":"Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive","enrollment":100},{"nctId":"NCT06538623","phase":"PHASE2","title":"Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2024-08-23","conditions":"Pancreatic Neoplasms, Neoplasm Metastasis, Hepatic Metastasis of Pancreatic Cancer","enrollment":40},{"nctId":"NCT07409272","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-17","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":614},{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT04248452","phase":"PHASE3","title":"Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-05-26","conditions":"Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","enrollment":314},{"nctId":"NCT07487610","phase":"","title":"Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older","status":"RECRUITING","sponsor":"Sultan 1. Murat State Hospital","startDate":"2026-03-17","conditions":"Neuropathic Pain, Old Age; Debility, Pain","enrollment":450},{"nctId":"NCT04233866","phase":"PHASE2","title":"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-08-26","conditions":"Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":176},{"nctId":"NCT06997497","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-16","conditions":"Colon Adenocarcinoma, Rectal Adenocarcinoma","enrollment":477},{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":"Colorectal Neoplasms","enrollment":1000},{"nctId":"NCT07043400","phase":"PHASE3","title":"A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-08-27","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":351},{"nctId":"NCT05379595","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-29","conditions":"Advanced or Metastatic Colorectal Cancer","enrollment":225},{"nctId":"NCT07480954","phase":"PHASE1, PHASE2","title":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-04","conditions":"Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma","enrollment":36},{"nctId":"NCT03684980","phase":"EARLY_PHASE1","title":"LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-11-14","conditions":"Central Nervous System Lymphoma","enrollment":58},{"nctId":"NCT03715933","phase":"PHASE1","title":"Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas","status":"RECRUITING","sponsor":"Inhibrx Biosciences, Inc","startDate":"2018-10-08","conditions":"Ewing Sarcoma","enrollment":321},{"nctId":"NCT02359968","phase":"PHASE2","title":"PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2015-02-26","conditions":"Esophageal Neoplasms, Gastro-esophageal Junction Cancer","enrollment":106},{"nctId":"NCT07011576","phase":"PHASE2","title":"A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2025-09-29","conditions":"Colon Cancer, Rectal Cancer, Colorectal Cancer","enrollment":60},{"nctId":"NCT05464030","phase":"PHASE1","title":"Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-08-04","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT07474727","phase":"PHASE2","title":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Multitude Therapeutics Inc.","startDate":"2026-04-01","conditions":"Colorectal Cancer","enrollment":180},{"nctId":"NCT06469944","phase":"PHASE1, PHASE2","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-20","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":160},{"nctId":"NCT05253651","phase":"PHASE3","title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-10-24","conditions":"Colorectal Neoplasms","enrollment":400},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT04300556","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","status":"RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-08-06","conditions":"Solid Tumor","enrollment":182},{"nctId":"NCT07024615","phase":"PHASE1","title":"A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-10-16","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":25},{"nctId":"NCT00905047","phase":"PHASE3","title":"Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2005-11-14","conditions":"Colorectal Cancer","enrollment":89},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT07469202","phase":"PHASE4","title":"CYTALUX Dose Extension Study","status":"NOT_YET_RECRUITING","sponsor":"On Target Laboratories, LLC","startDate":"2026-05-15","conditions":"Cancer in the Lung, Ovarian Cancer","enrollment":106},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06607185","phase":"PHASE1","title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-21","conditions":"Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":750},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":"Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated","enrollment":30},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":"Leukemia","enrollment":171},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT05751187","phase":"PHASE2","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-06-27","conditions":"Non-squamous NSCLC","enrollment":54},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT06780111","phase":"PHASE1, PHASE2","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":298},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":770},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT04040023","phase":"NA","title":"Patient Blood Management in Cardiac Surgery","status":"COMPLETED","sponsor":"Clinique Pasteur","startDate":"2019-09-10","conditions":"Surgical Blood Loss","enrollment":900},{"nctId":"NCT06555744","phase":"PHASE1","title":"A Study of ZW191 in Participants With Solid Tumors","status":"RECRUITING","sponsor":"Zymeworks BC Inc.","startDate":"2024-10-30","conditions":"Advanced Solid Tumors","enrollment":145},{"nctId":"NCT02047474","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03-25","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer","enrollment":46},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT05346484","phase":"PHASE1","title":"A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2022-05-17","conditions":"Solid Tumor, Solid Carcinoma, Solid Tumor, Adult","enrollment":66},{"nctId":"NCT04230187","phase":"PHASE3","title":"Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-09-01","conditions":"Colorectal Cancer","enrollment":528},{"nctId":"NCT02890355","phase":"PHASE2","title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-09-01","conditions":"Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7","enrollment":123},{"nctId":"NCT05677490","phase":"PHASE3","title":"mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-01-31","conditions":"Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":382},{"nctId":"NCT05568095","phase":"PHASE3","title":"A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2022-11-21","conditions":"Advanced Upper Gastrointestinal Tract Adenocarcinoma","enrollment":1040},{"nctId":"NCT05846867","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2023-05-08","conditions":"Colorectal Cancer","enrollment":170},{"nctId":"NCT04215731","phase":"PHASE3","title":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-03-27","conditions":"Rectal Cancer","enrollment":582},{"nctId":"NCT05579366","phase":"PHASE1, PHASE2","title":"Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-12-07","conditions":"High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma","enrollment":764},{"nctId":"NCT04094688","phase":"PHASE3","title":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2019-10-29","conditions":"Colorectal Adenocarcinoma","enrollment":455},{"nctId":"NCT07228832","phase":"PHASE3","title":"Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Summit Therapeutics","startDate":"2025-11-18","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":600},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT04068610","phase":"PHASE1, PHASE2","title":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2019-09-13","conditions":"Metastatic Microsatellite-stable Colorectal Cancer","enrollment":61},{"nctId":"NCT07441369","phase":"PHASE2","title":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Fudan University","startDate":"2026-03-01","conditions":"Liver Metastases From Colorectal Cancer (mCRC)","enrollment":16},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT07412613","phase":"PHASE3","title":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2026-03-15","conditions":"Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer","enrollment":386},{"nctId":"NCT07437287","phase":"PHASE2, PHASE3","title":"Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-07","conditions":"Biliary Tract Cancer (BTC)","enrollment":160},{"nctId":"NCT07435766","phase":"NA","title":"Iron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of Pregnancy","status":"RECRUITING","sponsor":"ETH Zurich","startDate":"2026-03-02","conditions":"Pregnancy","enrollment":50},{"nctId":"NCT06078709","phase":"PHASE2","title":"Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-20","conditions":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8","enrollment":99},{"nctId":"NCT07176182","phase":"PHASE2","title":"Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2026-03-01","conditions":"Rectal Cancer Patients, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":236},{"nctId":"NCT05329766","phase":"PHASE2","title":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2022-06-10","conditions":"Gastrointestinal Tract Malignancies","enrollment":332},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT03203525","phase":"PHASE1","title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-06-23","conditions":"Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver","enrollment":38},{"nctId":"NCT07432295","phase":"PHASE2","title":"Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)","status":"RECRUITING","sponsor":"I-Mab Biopharma US Limited","startDate":"2026-02","conditions":"Solid Tumor, Advanced Cancer, Metastatic Cancer","enrollment":180},{"nctId":"NCT06247787","phase":"PHASE1","title":"A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-02-04","conditions":"Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia","enrollment":36},{"nctId":"NCT07431281","phase":"PHASE3","title":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-03","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer","enrollment":2130},{"nctId":"NCT04430738","phase":"PHASE2","title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-09-15","conditions":"Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma","enrollment":40},{"nctId":"NCT06890338","phase":"PHASE2","title":"A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-21","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":140},{"nctId":"NCT05445778","phase":"PHASE3","title":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-03-15","conditions":"Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":520},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT02981628","phase":"PHASE2","title":"Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-06-19","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia","enrollment":80},{"nctId":"NCT05567835","phase":"PHASE2","title":"A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2024-03-06","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":3},{"nctId":"NCT05983367","phase":"PHASE2","title":"A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Inspirna, Inc.","startDate":"2023-10-10","conditions":"Colorectal Cancer, Metastatic Colon Cancer","enrollment":76},{"nctId":"NCT05647122","phase":"PHASE1","title":"First in Human Study of AZD9592 in Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-21","conditions":"Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms","enrollment":403},{"nctId":"NCT06835387","phase":"PHASE2","title":"Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors","status":"RECRUITING","sponsor":"Tiago Biachi de Castria","startDate":"2025-06-30","conditions":"Small Bowel Adenocarcinoma","enrollment":36},{"nctId":"NCT03388190","phase":"PHASE2","title":"METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin","status":"COMPLETED","sponsor":"University Hospital, Akershus","startDate":"2018-05-29","conditions":"Colorectal Cancer Metastatic","enrollment":80},{"nctId":"NCT06750094","phase":"PHASE3","title":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT05365581","phase":"PHASE1","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-06-07","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":398},{"nctId":"NCT03504397","phase":"PHASE3","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-06-21","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":565},{"nctId":"NCT05067283","phase":"PHASE1","title":"A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-12-17","conditions":"Advanced Solid Tumors","enrollment":830},{"nctId":"NCT07405190","phase":"PHASE2","title":"Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-08-04","conditions":"Lung Cancer (NSCLC), Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer (Non-Small Cell)","enrollment":46},{"nctId":"NCT06501989","phase":"PHASE2","title":"Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2025-09-19","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT03983057","phase":"PHASE2","title":"Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-04-01","conditions":"Pancreatic Cancer","enrollment":392},{"nctId":"NCT04340141","phase":"PHASE3","title":"Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2020-10-13","conditions":"Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer","enrollment":358},{"nctId":"NCT05919264","phase":"PHASE1, PHASE2","title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Parabilis Medicines, Inc.","startDate":"2023-05-23","conditions":"Cancer, Colorectal Cancer, Solid Tumor","enrollment":575}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":75449,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Folic acid or folate","genericName":"Folic acid or folate","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Folic acid acts as a coenzyme in one-carbon transfer reactions essential for DNA synthesis and cell division. Used for Folic acid deficiency anemia, Neural tube defect prevention in pregnancy, Megaloblastic anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}